Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland

  • M. Patrzałek
  • P. AlbrechtEmail author
  • M. Sobczynski


This study was performed to estimate the effect of heptavalent pneumococcal conjugate vaccine (PCV7) on the pneumonia admission rate in children younger than 5 years of age, after the introduction of routine 2+1 dose schedule immunization. We compared the pneumonia admission rate (number of cases per 1,000 population) 2 years before and 2 years after the introduction of PCV7 in 2006. Only children with radiologically confirmed pneumonia were analyzed. The vaccination rate in the analyzed periods was around 99%. In the period preceding the implementation of PCV7, the average pneumonia admission rate was 41.48/1,000 and 6.15/1,000 for 1-year-old and 2–4-year-old children, respectively. Statistical analysis showed a significant fall in this rate in two consecutive years after PCV7 implementation (p < 0.0000001 for 1-year-old and p = 0.011 for 2–4-year-old children, respectively). In the first year of vaccination, the admission number decreased in these two groups by about 65 and 23%, respectively. In the second year, only a few percent fall in the admission rate was noted. In children younger than 2 years of age, the age group targeted for vaccination, pneumonia-related healthcare utilization declined substantially following PCV7 introduction. These results suggest that PCV7 may play an important role in reducing the burden of pneumonia in Poland.


Pneumonia Invasive Pneumococcal Disease Pneumococcal Pneumonia Herd Immunity Pneumococcal Conjugate Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C (2002) Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2:25–32CrossRefPubMedGoogle Scholar
  2. 2.
    WHO Global Immunization Vision and Strategy, April 2005. Available online at:
  3. 3.
    Foy HM, Cooney MK, Allan I, Kenny GE (1979) Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 241:253–258CrossRefPubMedGoogle Scholar
  4. 4.
    Murphy TF, Henderson FW, Clyde WA Jr, Collier AM, Denny FW (1981) Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol 113:12–21PubMedGoogle Scholar
  5. 5.
    McConnochie KM, Hall CB, Barker WH (1988) Lower respiratory tract illness in the first two years of life: epidemiologic patterns and costs in a suburban pediatric practice. Am J Public Health 78:34–39CrossRefPubMedGoogle Scholar
  6. 6.
    Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, Kauppila J, Leinonen M, McCracken GH Jr (2004) Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 113:701–707CrossRefPubMedGoogle Scholar
  7. 7.
    Korppi M, Heiskanen-Kosma T, Jalonen E, Saikku P, Leinonen M, Halonen P, Mäkela PH (1993) Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr 152:24–30CrossRefPubMedGoogle Scholar
  8. 8.
    Drummond P, Clark J, Wheeler J, Galloway A, Freeman R, Cant A (2000) Community acquired pneumonia—a prospective UK study. Arch Dis Child 83:408–412CrossRefPubMedGoogle Scholar
  9. 9.
    Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19:187–195CrossRefPubMedGoogle Scholar
  10. 10.
    Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J (2002) Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21:810–815CrossRefPubMedGoogle Scholar
  11. 11.
    Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369:1179–1186CrossRefPubMedGoogle Scholar
  12. 12.
    Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP (2007) Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 161:1162–8CrossRefPubMedGoogle Scholar
  13. 13.
    Adam D, Fehnle K (2008) Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Vaccine 26(47):5944–5951CrossRefPubMedGoogle Scholar
  14. 14.
    Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V, Marensi L, Giacchino R, Timitilli A, Carloni R, Azzari C, Icardi G; Collaborative Group for Pneumococcal Vaccination in Liguria (2009) Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 27(25–26):3459–3462CrossRefPubMedGoogle Scholar
  15. 15.
    Käyhty H, Åhman H, Eriksson K, Sörberg M, Nilsson L (2005) Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 24:108–114CrossRefPubMedGoogle Scholar
  16. 16.
    Esposito S, Pugni L, Bosis S, Proto A, Cesati L, Bianchi C, Cimino C, Mosca F, Principi N (2005) Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 23:1703–1708CrossRefPubMedGoogle Scholar
  17. 17.
    R Development Core Team (2005) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Home page at:
  18. 18.
    Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA; Gambian Pneumococcal Vaccine Trial Group (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365:1139–1146CrossRefPubMedGoogle Scholar
  19. 19.
    Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group (2003) A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349:1341–1348CrossRefPubMedGoogle Scholar
  20. 20.
    O’Brien KL, Dagan R (2003) The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 21:1815–1825CrossRefPubMedGoogle Scholar
  21. 21.
    Levine OS, O’Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, Dagan R, Goldblatt D, Grange A, Greenwood B, Hennessy T, Klugman KP, Madhi SA, Mulholland K, Nohynek H, Santosham M, Saha SK, Scott JA, Sow S, Whitney CG, Cutts F (2006) Pneumococcal vaccination in developing countries. Lancet 367:1880–1882CrossRefPubMedGoogle Scholar
  22. 22.
    McIntosh K (2002) Community-acquired pneumonia in children. N Engl J Med 346:429–437CrossRefPubMedGoogle Scholar
  23. 23.
    Advisory Committee on Immunization Practices (2000) Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49(RR-9):1–35Google Scholar
  24. 24.
    Grzesiowski P, Skoczynska A, Albrecht P, Konior R, Patrzalek M, Sadowska M, Staroszczyk J, Szenborn L, Wysocki J, Hryniewicz W; Polish Pediatric IPD Group (2008) Invasive pneumococcal disease in children up to 5 years of age in Poland. Eur J Clin Microbiol Infect Dis 27:883–885CrossRefPubMedGoogle Scholar
  25. 25.
    Grijalva CG, Edwards KM (2006) Promises and challenges of pneumococcal conjugate vaccines for the developing world. Clin Infect Dis 43:680–682CrossRefPubMedGoogle Scholar
  26. 26.
    Wardlaw T, Salama P, Johansson EW, Mason E (2006) Pneumonia: the leading killer of children. Lancet 368:1048–1050CrossRefPubMedGoogle Scholar
  27. 27.
    Mulholland K (2005) The Gambian pneumococcal vaccine trial—implications for control of childhood pneumonia. Trop Med Int Health 10:497–500CrossRefPubMedGoogle Scholar
  28. 28.
    van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, Bruin JP, van Alphen L, Sanders EA (2009) Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 302:159–167CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Specialty Children’s HospitalKielcePoland
  2. 2.Warsaw Medical UniversityWarsawPoland
  3. 3.Medical University of WroclawWroclawPoland

Personalised recommendations